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Background.Changesinperipheralmuscleinheartfailureleadtoashiftfromaerobictoearlyanaerobicmetabolismduringexercise
leading to ergoreﬂex overactivation and exaggerated hyperventilation evaluated by the VE/VCO2 slope. Methods.5 0p a t i e n t s
(38 males, 59 ± 12 years) performed cardio-pulmonary exercise test with gaz exchange measurement and echocardiographic
evaluation before and 6 months after CRT. Results. The peak respiratory exchange (VCO2/V O 2) ratio was signiﬁcantly reduced
from 1.16±0.14to 1.11±0.07(P<. 05) and the timeto the anaerobicthreshold was increased from 153±82 to 245±140seconds
(P = .01).Peak VO2,V E / V C O 2,peak circulatory power andNYHA were improved after CRT (13±4t o16±5ml / kg / mi n(P<. 05),
45 ± 16 to 39 ± 13 (P<. 01), 1805 ± 844 to 2225 ± 1171mmHg.ml/kg/min (P<. 01) and 3 ± 0.35 to 1.88 ± 0.4( P = .01)). In
addition, left ventricular ejection fraction and end-systolic volumes were improved from 24 ± 8t o2 9± 7% (P<. 01) and from
157 ± 69 to 122 ± 55 ml (P<. 01). Conclusion. We suggest that CRT leads to an increase in oxidative muscular metabolism and
postponed anaerobic threshold reducing exaggerated hyperventilation during exercise.
1.Introduction
It remains unclear how cardiac resynchronization therapy
(CRT) improves symptom status in heart failure population.
CRT is one of the major treatment for patients suﬀering
from refractory heart failure (HF) despite an optimal drug
regimen [1]. Huge previous trialsconﬁrmed improvement
in both symptom status (NYHA class) and remodelling
parameters (left ventricular (LV) ejection fraction, mitral
regurgitation, and LV end-systolic volume) [2]. In addition,
objective functional parameters are improved by CRT (peak
oxygen uptake, 6-minute walking test, peak workload,
exercise duration) [3]. It was well conﬁrmed that heart
failure patients present an exaggerated hyperventilationchar-
acterised by an increase in the slope relating the minute
ventilationtocarbondioxideproduction(VE/VCO2)leading
to early fatigue and breathlessness during the eﬀort [4].
Physiopathological determinants of such an hyperventi-
lation remain unclear. Nevertheless, an important cause of
hyperpnea during eﬀort is the enlargement of physiological
dead space and ventilation-perfusion mismatch by alveolar
hypoperfusion from hemodynamic dysfunction. Another
determinant is the early cardiorespiratory reﬂex dysregula-
tion. This was evidenced by increased peripheral and cen-
tral chemosensitivity, impaired sympathovagal balance with
sympathetic predominance, and depressed baroreﬂex circu-
lation control [5, 6]. In addition, in heart failure population,
the skeletal musculature has been extensively investigated.
Muscle bulk is known to be reduced, and abnormalities of
muscle function, histologic features, and metabolism have
all been described [7]. In particular, both reduction in
capillary density and shift from slow-twitch-type 1 muscular
ﬁbres to fast-twitch-type 2 ﬁbres were found. It leads to
depressed oxidative capacity bya reductionin mitochondrial
density and increases the glycogenolytic metabolism, the
carbon dioxide production, and the respiratory exchange
ratio at peak of the exercise (VCO2/VO2)[ 8]. These mus-
cular modiﬁcations are associated with an overactivation of2 Cardiology Research and Practice
the peripheral ergoreﬂex leading to an early hyperventilation
during exercise (the “muscle hypothesis”) [9].
We suggest that reduction in exaggerated hyperventila-
tion during exercise in HF population after CRT is linked to
an improvement in musculature metabolism, which results
in increasing oxidative metabolism, reducing the respiratory
exchange ratio at peak of the exercise, and improving the
time to anaerobic threshold (AT).
2.Methods
Fifty consecutive refractory HF patients were enrolled in
this single center investigation. All those patients matched
the following criteria: indication for CRT implantation
according to current indications (QRSduration >120ms, LV
ejection fraction <35%, NYHA symptom class II-III or IV,
and optimal heart failure medical regimen) [10]. Complete
echocardiographicevaluationincludingLVvolumemeasure-
ments and a cardiopulmonary exercise were realized before
and 6 months after CRT implantation. Patients with history
of chronic lung diseases were excluded.
2.1. Echocardiographic Measurement. Echocardiograms were
loaded into a computer system (Echopac, GE), and all
measurementswereobtainedforallpatientsatbaselineand6
months after implantation. Echocardiograms were analyzed
by a single experienced sonographer.
Sample loops were analyzed oﬀ line on an Echopac com-
puter workstation to obtain end-diastolic (EDV) and end-
systolic LV (ESV) volumes using the methods of disks. Ejec-
tion fraction was calculated as follows: (EDV−ESV)/EDV×
100%. Mitral regurgitation was evaluated according to the
European Society of Echocardiography [11].
2.2. Testing Procedure and Data Collection. As y m p t o m -
limited exercise test with ventilatory expired gas analysis
using a cycle ergometer with a 10Watts/minute protocol was
performed in all patients in an air conditioned room (Ergo
Card, Medisoft, Sorinnes, Belgium). Continuous standard
12leadelectrocardiograms, manual bloodpressure measure-
ments, and heart rate recordings were monitored at every
stage. Data for oxygen consumption (VO2), carbon dioxide
production (VCO2), minute ventilation (VE), respiratory
rate (RR), and work load were collected continuously
throughout the exercise. Oxygen and carbon dioxide sensors
were calibrated using gases with known oxygen, nitrogen,
and carbon dioxide concentrations prior to each test.
Ventilatory eﬃciency was obtained by the linear regression
slope relating VE to VCO2 from the beginning to the peak
of the eﬀort [12]. Peak VO2 w a su s e da sa ni n d e xo fe x e r c i s e
capacity.
The peak circulatory power was measured as an evalu-
ation of the cardiac pumping function by the product of
the peak VO2 and the systolic blood pressure as described
by Cohen-Solal et al. [13]. The respiratory exchange ratio
(RER) was measured by the rapport between the carbon
dioxide production (VCO2) and the oxygen consumption
(VO2). The peak RER was used in this study. The anaerobic
threshold was assessed using Wasserman’s method. All
exercises were realized after written agreements of patients.
2.3. Subgroup Analysis. the responders and the nonrespon-
ders to the CRTwere characterized. The responder subgroup
was deﬁned as having a telesystolic LV volume reduction
greater than 15% after CRT [14].
2.4. Statistical Analysis. Paired t tests were used to compare
diﬀerencesbetweenparameters at baseline and afterCRT.All
statistical tests with a P value of <.05 were considered to be
signiﬁcant. Continuousvariablesaresummarized bymean ±
SD.
3.Results
3.1. Patients. Baseline characteristics of patients includedare
summarized in Table 1. Heart failure etiology was ischaemic
in 46% and nonischaemic in 54%. Patients had severely
depressed LV function with a mean LV ejection fraction of
24 ± 8%. Mean NYHA symptom class was 2,98 ± 0,35, and
mean QRS duration was 154 ± 35ms. Mean values of peak
VO2 and VE/VCO2 slope were 13 ± 4ml/kg/minute and
45 ± 16. Mean maximal work load at peak of the exercise
and the mean peak circulatory power were 78 ± 28Watts
and 1805 ± 744mmHg·ml/kg/min. Mean peak RER was
ml/min, 1,16 ± 0,14. EDV and ESV were 205 ± 79ml and
157 ± 69ml, respectively. Mean mitral regurgitation grade
was 1,49 ± 1.
3.2. 6-Month Followup after CRT. At 6 months, mean values
of NYHA,peak VO2,V E / V C O 2 slope and RER at the peak
were 1,88 ± 0,4 (P<. 01),16 ± 5ml/kg/min(P<. 05),39 ±
13 (P<. 01) and 1,11 ± 0,07 (P<. 05), respectively. Mean
time to anaerobic threshold was improved from 153 ± 82 to
245 ± 140 seconds (P = .01). Left ventricular remodelling
parametersweresigniﬁcantlyimproved.MeanvaluesofEDV,
ESV, and ejection fraction were 175 ± 71ml (P<. 01),
122 ± 55ml (P<. 01), and 31 ± 8% (P<. 01), respectively.
Eﬃcient biventricular pacing was assessed by CRT control at
6m o n t h s .
3.3. Subgroup Analysis. 23 patients (18 males, 61 ± 10 years)
(46%) were included in the nonresponder subgroup. Major
HF etiology was ischaemic in 56%, and mean QRS duration
was 144 ± 39ms.
In this population, NYHA symptom was improved from
2,83 ± 0,5 to 2 ± 0,34 (P<. 01). Peak VO2,V e / V C O 2 slope,
RER, and RR did not change (13 ± 2t o1 5± 5ml/kg/min,
46±10 to 41 ± 8,1, 14 ± 0,14 to 1,1 ± 0,07, and 30 ± 4t o
27 ± 4/min, respectively; P>. 05). Mean time to anaerobic
threshold was not signiﬁcantly increased from 183 ± 90 to
225 ± 122 seconds (P>. 05). No signiﬁcant increase in
exercise duration and peak workload was found 6 months
after CRT. Rest HR was decreased from 77 ± 16bpm to
73 ± 9bpm(P>. 05), and peak circulatory power did not
change from 1733 ± 480 to 2021 ± 803mmHg·ml/kg/min
(P>. 05). In this subgroup, LV tele-systolic, ejection fractionCardiology Research and Practice 3
Table 1: Populationcharacteristics before and after CRT.




Age, yrs 59 ± 12




SBP at rest, mmHg 108 ±18 107 ±17 >.05
SBP at peak, mmHg 131 ±22 135 ±28 >.05
HR at rest, bpm 81 ± 18 73 ±11 <.05
HR at peak, bpm 116 ±23 114 ±27 >.05
Peak of VO2,m l / k g / m i n 1 3±41 6 ±5 <.05
VE/VCO2 slope 45 ± 16 39 ±13 <.05
AT (seconds) 153 ±82 245 ±140 .01
AT VO2 10 ±21 2 ±4 <.05
Peak CP, mmHg·ml/kg/min 1805 ±744 2225 ±1071 <.01
Maximalwork load, Watts 78 ± 28 86 ±26 <.05
Peak RER 1,16 ± 0,14 1,11 ±0,07 <.05
Peak respiratory rate, /min 30 ±82 7 ±6. 0 1
Exercise duration, seconds 406 ± 175 449 ±164 .01
NYHA class 2,98 ± 0,35 1,88 ±0,4 <.01
Left ventricular end-systolic volume, ml 157 ±69 122 ±55 <.01
Left ventricular end-diastolic volume, ml 205 ±79 175 ±71 <.01
Mitral regurgitation, grade 1.49 ±11 .12 ±0.9 <.05
QRS duration, ms 154 ±35
Beta-blocker, % 95
Diuretic, % 83
Angiotensin-converting enzym inhibitor, % 85
AT: anaerobic threshold, CP: circulatory power, HR: heart rate, Ms: milliseconds, NYHA: New York Heart Association, RER: respiratory exchange ratio, SBP:
Systolic blood pressure, VCO2: carbon dioxide production, VE: minute ventilation, VO2: oxygen consumption, and yrs: years.
and mitral regurgitation were measured from 26 ± 7t o
27 ± 8%, from 137 ± 0,11 to 143 ± 44ml, and from1,06 ±
0,87 to 0,89 ± 0,96 (all P>. 05).
27patients(20males,58±14years)(54%)wereincluded
in the responder subgroup. QRS duration at baseline was
162 ± 29ms and an ischaemic cause was found in 37%.
NYHA symptom class was improved from 3 ± 0,3 to
1,78 ± 0,42 (P<. 01).Peak HR was decreased from 85 ± 21
to 71 ± 13bpm (P<. 05). Peak VO2,V E / V C O 2 slope,
RER, RR, exercise duration, peak circulatory power, peak
workload, and peak respiratory rate were improved from
14 ± 5t o1 6± 5ml/kg/min(P<. 05), 45 ± 20 to 38 ± 15
(P<. 01), 1,17 ± 0,14 to 1,11 ± 0,07 (P<. 05), 31 ± 11
to 27 ± 7/min (P<. 05), 409 ± 200 to 460 ± 193 seconds
(P<. 05), 1862 ± 907 to 2384 ± 1235 mmHg·ml/kg/min
(P = .01),78 ± 31 to 89 ± 33watts (P<. 01), and 31±10 to
27 ± 7/min (P<. 05). Mean time to anaerobic threshold
was improved from 133 ± 5 to 261 ± 154 seconds (P =
.01). In addition, LV ejection fraction, telesystolic volume,
and mitral regurgitation were improved from 22 ± 8t o
34 ± 7% (P<. 01), 173 ± 81 to 106 ± 59ml (P<. 01), and
from grade1,83 ± 0,94 to1,3 ± 0,76 (P<. 01),respectively.
4.Discussion
Reduction in the RER at peak (despite signiﬁcant increase
in exercise parameters) and improvement in the time to AT
suggest a postponed muscular anaerobic metabolism during
exercise 6 months after CRT, in particular in responder
subgroup.
It was clearly conﬁrmed that patients suﬀering from
heart failure have muscular dysfunctions leading to an early
anaerobic metabolism with a high production in carbon
dioxide and a reduction in the oxygen consumption during
exercise [15]. Skeletal muscle blood ﬂow is limited in HF
population probably due to a combination of low cardiac
output and increased peripheral resistance as sympathetic
tone overactivation and endothelial dysfunction leading
to a reduction in muscular capillary density [16, 17].4 Cardiology Research and Practice
There is also evidence of a reduced percentage of slow-
twitch-type 1 ﬁbres with high oxidative enzyme content
and an increased percentage of type 2B ﬁbres with high
glycolytic capacity. In addition, previous trials conﬁrmed a
reduction in oxidative enzyme activity and in mitochondrial
density and a phosphocreatine depletion leading to lactate
accumulation. In response to metabolic distress in exercising
muscle an exaggerated ergoreﬂex activation was found. This
leads to excessive reﬂex sympathetic tone. Large previous
trials conﬁrmed an important ergoreﬂex overactivation in
heart population correlated with exaggerated hyperventi-
lation during exercise [18, 19]. This model represents the
“muscle hypothesis.’’
In our investigation, the ventilatory response evaluated
by the linear regression slope relating the minute ventilation
to the carbon dioxide production was signiﬁcantly improved
in particular in the responder subgroup as previously
described [20]. In addition, heart rate at rest and peak
respiratory rate were reduced after CRT implantation, in
particular in the responder subgroup, suggesting a reduction
in sympathetic tone. 95% of patients were treated with
beta blockers before and after CRT without increase during
followup. Heart rate reduction was previously described in
a study by Wasserman et al. after CRT (P<. 001 compared
with baseline in the CRT-on group and P<. 01 in the CRT-
oﬀ group) [21]. The eﬀects of long-term beta blockade were
demonstrated in heart failure population with a reduction
in both ventilatory parameters (peak minute ventilation,
peak carbon dioxide production, and respiration rate) and
haemodynamic parameters (LV ejection fraction, heart rate
and blood pressure) [22].
Inaddition,leftventricularvolumesandejectionfraction
were improved as well as the peak circulatory power. This
simple haemodynamic noninvasive parameter was described
to be a close approach of the “cardiac power” (production
of both the cardiac output and the main blood pressure) for
theevaluationofthecardiacpumpingfunction.The peakCP
was measured by the product of the peak VO2 and the SBP at
peak ofthe exercise as described previously. It was conﬁrmed
that the peak CP is a strong prognostic marker in heart
failure population. It incorporates arteriovenous diﬀerence,
heart rate, stroke volume, and blood pressure responses at
peak of the exercise [13]. Haemodynamic condition was
clearly improved after CRT implantation, in particular for
the responder subgroup.
In the nonresponder subgroup, no signiﬁcant improve-
ment was found in the haemodynamic parameters (LV
ejection fraction, peak circulatory power) associated with
a nonsigniﬁcant improvement in both exercise capacity
and ventilatory response. In addition, in this population
no signiﬁcant decrease in peak RER and in time to AT
was found, suggesting a persistent early muscular anaerobic
metabolism.
We suggest that CRT leads to an improvement in
peripheralbloodﬂowbybetterhaemodynamic conditions.It
could lead to a shift from fast-twitch-type 2B ﬁbres to slow-
twitch-type1ﬁbreswithanincreaseinoxidativemetabolism,
in mitochondrial density, and in oxygen consumption
and in reduction in carbon dioxide production resulting in
a postponed AT and in lower peak RER.
Muscular biopsies with mitochondrial density, oxidative
enzymes, and capillary density measurements are needed
to conﬁrm our data. We could correlate biopsy results
with ventilatory response and time to AT after CRT. The
lack of histology support was the main limitation in our
investigation. In addition, this prospective study was not a
randomized control trial.
5.Conclusion
CRT improves haemodynamic condition and exercise capac-
ity and reduces the ventilatory response during eﬀort. In
addition, CRT decreases the peak respiratory exchange ratio
suggesting the possibility of increased eﬃciency of energy
productioninskeletalmusclewithlessanaerobicmetabolism
by a shift from a glycolytic to an oxidative metabolism.
Link between the improvement in the peak RER, the
ventilatorydata,and thehaemodynamic parameters suggests
a reduction in the sympathetic tone explained by a decrease
intheergoreﬂexactivity.But,largefurtherstudiesareneeded
to conﬁrm our data.
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